Konstantinos serves as Co-Managing Partner of the Brain AI Fund.

Acclaimed company builder and product developer with a track record of scaling healthcare companies & bringing innovative therapeutics to market including the first commercially viable Brain AI therapy for neurological conditions. Founder (2006) and former CEO of Nevro (NYSE: NVRO) led the product development and market introduction of the first advanced AI-powered brain therapy.

Board of Directors at Precision Neuroscience and Oryzon Genomics. Chair of the Specific Advisory Board of Iota Biosciences (acquired by Astellas Pharma). Previously an investor for the Pritzker Family Healthcare fund and was a business development executive at Boston Scientific.

PhD in Computational Neuroscience with a focus on Artificial Neural Networks.  BE and MS in Electrical Engineering and Computer Science.